Dr. Klausner Co-Chairs Committee Preparing NAS Terrorism Report

Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

WASHINGTON-A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

WASHINGTON—A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

Dr. Klausner and Lewis M. Branscomb, PhD, Albert Pratt Public Service Professor at Harvard University’s John F. Kennedy School of Government, co-chair the committee. About 150 outside experts and consultants are contributing to the effort, which is expected to inform the decision-making process for the fiscal year 2004 budget.

In addition to his NAS commitment, Dr. Klausner continues to pursue research part time at NCI. He resigned as director last fall after more than 6 years in the post. He originally left to head a new institute established by the Case Foundation of AOL founder Steven Case and his wife, but the Cases withdrew their commitment to the project.

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma
Related Content